By Ian Walker

AstraZeneca PLC said Wednesday that it has transferred the global rights to Eklira and Duaklir to Covis Pharma Group for a sum of $270 million.

The pharmaceutical giant added that it will also receive payments for certain continuing development costs related to the medicines.

Eklira and Duaklir are inhaled respiratory medicines used to maintain treatment of chronic obstructive pulmonary disease.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

January 05, 2022 02:26 ET (07:26 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Astrazeneca.
Astrazeneca (LSE:AZN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Astrazeneca.